A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Naurex
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 12 Jul 2019 This trial was discontinued in Slovakia, Bulgaria and Hungary (end date: 2019-06-20), according to European Clinical Trials Database.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.